The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.

An enzyme pulled from toxic bacteria can enter the organelle and perform single-nucleotide DNA swaps.

In demonstrations in cell lines, the technique has a similar efficacy to CRISPR-Cas9, but fewer off-target effects.

A new study indicates that the modified CRISPR-Cas9 technology will need to be further refined before it can safely be used for research and therapeutic applications.

Adenine editing enzymes have been adapted for use in plants.

Adenine editing enzymes have been adapted for use in plants.

Separate proof-of-concept studies report success against two inherited diseases.

With the arrival of a new class of single-nucleotide editors, researchers can target the most common type of pathogenic SNP in humans.

Researchers use base-editing to swap out an erroneous nucleotide responsible for a potentially life-threatening blood disorder.

Combining a modified Cas9 enzyme with an unrelated one derived from the immune system of the sea lamprey, researchers demonstrate yet another way to edit a single DNA nucleotide. 

Researchers develop a CRISPR-based technique that efficiently corrects point mutations without cleaving DNA.